Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALARMONY: GSK3862995B and GSK5784283 in Moderate to Severe COPD
NCT07915791Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
- Primary completion
- Mar 2029
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GSK3862995B + GSK5784283 with Placebo (2 arms). Primary endpoint: Annualized Rate of Moderate/severe Exacerbations at 72 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
gsk3862995bfelcorekibart
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07915791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07915791.